Is It Time To Reconsider Hologic (HOLX) After Mixed Returns And DCF Upside?

Simply Wall St.01-15

If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603860487?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-15 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603860487","market":"nz","top_or_hot":-1,"title":"Is It Time To Reconsider Hologic (HOLX) After Mixed Returns And DCF Upside?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-holx/hologic/news/is-it-time-to-reconsider-hologic-holx-after-mixed-returns-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reconsider Hologic (HOLX) After Mixed Returns And DCF Upside?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reconsider Hologic (HOLX) After Mixed Returns And DCF Upside?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-holx/hologic/news/is-it-time-to-reconsider-hologic-holx-after-mixed-returns-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-holx/hologic/news/is-it-time-to-reconsider-hologic-holx-after-mixed-returns-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-holx/hologic/news/is-it-time-to-reconsider-hologic-holx-after-mixed-returns-an","article_id":"2603860487","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-holx/hologic/news/is-it-time-to-reconsider-hologic-holx-after-mixed-returns-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603860487","pubTimestamp":1768465606,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value.\nThe stock last closed at US$75.16, with returns of 0.3% over the past week, around 0.0% over the last month, 0.8% year to date, 9.3% over 1 year, a 4.8% decline over 3 years, and a 2.7% decline over 5 years, which gives you a mixed picture of recent and longer term performance.\nRecent coverage around Hologic has focused on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4588":"碎股","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4585":"ETF&股票定投概念","HOLX":"豪洛捷","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4082":"医疗保健设备","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD"},"translate_title":"在混合回报和DCF上涨之后，是时候重新考虑Hologic(HOLX)了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1.5,"HOLX":1.5},"content_text":"If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$75.16, with returns of 0.3% over the past week, around 0.0% over the last month, 0.8% year to date, 9.3% over 1 year, a 4.8% decline over 3 years, and a 2.7% decline over 5 years, which gives you a mixed picture of recent and longer term performance. Recent coverage around Hologic has focused on its role in women’s health and diagnostics, as investors continue to track how this focus fits with broader healthcare trends. This context is important when you look at the modest near term share price moves alongside more muted multi year returns. On Simply Wall St’s 6 point valuation checklist Hologic scores a 4. This means it screens as undervalued on four of the six measures. Next we will walk through the key valuation approaches before finishing with a way to think about value that goes beyond the usual multiples and models.  Hologic delivered 9.3% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. AdvertisementApproach 1: Hologic Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes projected future cash flows, then discounts them back to today to estimate what the entire business could be worth right now. For Hologic, the model uses last twelve months Free Cash Flow of about $905.8 million as the starting point, then builds out a 2 stage Free Cash Flow to Equity profile. Analyst inputs cover the earlier years, and Simply Wall St extrapolates beyond that. For example, projected Free Cash Flow for 2026 is $1,052 million, rising to a projected $1,512.7 million by 2035, all in dollar terms and then discounted back to today. When those discounted cash flows are added up, the DCF model arrives at an estimated intrinsic value of about $105.51 per share. Compared with the recent share price of $75.16, this implies Hologic screens as approximately 28.8% undervalued under these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Hologic is undervalued by 28.8%. Track this in your watchlist or portfolio, or discover 878 more undervalued stocks based on cash flows. HOLX Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Hologic. Approach 2: Hologic Price vs Earnings For a profitable business like Hologic, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It ties the share price directly to profits, which many investors focus on first when comparing companies. What counts as a “normal” or “fair” P/E hinges on what the market expects for future growth and how risky those earnings are perceived to be. Higher expected growth and lower perceived risk can justify a higher multiple, while slower growth or higher risk usually point to a lower one. Hologic currently trades on a P/E of 29.62x. That sits below the peer average of 53.82x and close to the Medical Equipment industry average of 31.01x. Simply Wall St also calculates a “Fair Ratio” for Hologic of 29.05x. This proprietary metric estimates the P/E you might expect given factors such as the company’s earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it is tailored to Hologic, it can be more informative than a simple comparison with broad industry or peer group averages. With the current P/E of 29.62x only slightly above the Fair Ratio of 29.05x, the shares screen as about right on this metric. Result: ABOUT RIGHT NasdaqGS:HOLX P/E Ratio as at Jan 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1440 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Hologic Narrative Earlier we mentioned that there is an even better way to think about value, and on Simply Wall St that starts with Narratives. This is where you set out your story for Hologic, link it to your own forecast for revenue, earnings and margins, and the platform then turns that into a Fair Value you can compare with the current price. It updates automatically as news or earnings arrive, and you can see it alongside other investors on the Community page. For example, one Hologic Narrative might lean closer to the higher analyst price target of US$94 with stronger assumptions for long term women’s health demand and AI supported diagnostics. Another might sit nearer the lower US$65 target, focusing more on risks around tariffs, China exposure and lower growth segments. Those different stories naturally lead to different views on whether the current share price looks attractive or not. Do you think there's more to the story for Hologic? Head over to our Community to see what others are saying! NasdaqGS:HOLX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hologic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603860487","isCrawlerRequest":true}